Clinical Trial Update: Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea

View source ↗

Summary

A post-marketing surveillance study conducted in Korea assessed treatment-emergent adverse events in patients with type 2 diabetes taking exenatide over 12 to 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• EXENATIDE (EXENATIDE)

Snippet

Sponsor: AstraZeneca | Conditions: Diabetes Mellitus Type 2 | Status: COMPLETED